Table 2 Effect of Vitamin D3 supplementation on obese type 2 diabetic subjects
Variable | Vitamin D-group | Placebo group | ||||
|---|---|---|---|---|---|---|
Baseline | Phase 1 (6000 IU/day) | Phase 2 (3000 IU/day) | Baseline | Phase 1 | Phase 2 | |
Weight (kg) | 95.5±17.7 | 95.0±18.1 | 94.7±18.2 | 94.2±23.3 | 95.0±23.4 | 95.2±23.4 |
Systolic blood pressure (mm Hg) | 128±20 | 133±16 | 133±12 | 131±18 | 132±19 | 133±19 |
Diastolic blood pressure (mm Hg) | 70±12 | 74±9 | 73±9 | 73±9 | 73±10 | 73.±9 |
S-25(OH) vitamin D (nmol/l) | 28.5±9.2 | 77.2±30.1a | 62.3±20.8ab | 30.5±11.3 | 28.8±12.9 | 25.4±11.8a |
P-calcium (mmol/l) | 2.31±0.08 | 2.31±0.89 | 2.30±0.89 | 2.35±0.10 | 2.32±0.11 | 2.29±0.10a |
P-phosporous (mmol/l) | 1.16±0.18 | 1.21±0.16 | 1.17±0.13 | 1.17±.14 | 1.20±0.21 | 1.10±0.18 |
P-parathyroid hormone(pmol/l) | 5.9±2.4 | 5.0±2.5 | 4.5±1.8a | 5.4±2.3 | 5.4±2.4 | 5.5±2.4 |
P-alkaline phosphotase (IU/l) | 73.9±17.7 | 69.4±16.7 | 69.5±16.0 | 81.2±22.6 | 76.3±22.5 | 77.9±24.6 |
P-fasting glucose (mmol/l) | 9.3±2.8 | 9.8±3.1 | 9.5±2.9 | 8.9±3.2 | 9.2±3.4 | 9.7±3.7 |
B-HbA1c (%) | 8.2±1.3 | 8.2±1.4 | 8.0±1.5 | 8.3±1.8 | 8.4±1.8 | 8.3±1.9 |
P-C-peptide (nmol/l) | 1.2±0.5 | 1.3±0.5 | 1.2±0.5 | 1.0±0.4 | 1.0±0.4 | 1.0±0.4 |
P-CRP (mg/l) | 7.4±7.6 | 7.8±10.8 | 8.0±9.5 | 8.0±9.2 | 9.5±10.4 | 10.0±13.0 |
P-creatinin (mmol/l) | 55.5±14.3 | 57.1±20.3 | 54.3±13.1 | 54.0 ±16.1 | 51.6±13.6 | 53.0±15.2 |
P- cholesterol (mmol/l) | 4.3±1.0 | 4.2±0.9 | 4.3±1.0 | 4.1±0.9 | 4.0±0.8 | 4.3±1.3 |
P-HDL-cholesterol (mmol/L) | 1.1±0.2 | 1.1±0.2 | 1.1±0.2 | 1.1±0.3 | 1.1±0.2 | 1.1±0.2 |
P-LDL-cholesterol (mmol/l) | 2.7±0.8 | 2.5±0.8 | 2.6±0.9 | 2.4±0.8 | 2.4±0.8 | 2.5±1.0 |
P-Triglyceride (mmol/l) | 1.6±1.1 | 1.7±1.1 | 1.6±0.8 | 1.8±1.1 | 1.8±1.4 | 1.9±1.8 |
